CDC Updates RSV Vaccination Recommendation for Adults
WEBJun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone ages 75 and older receive the RSV vaccine.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way.
Federal Officials Revise Recommendations for R.S.V. Vaccine
WEBJun 26, 2024 · The Food and Drug Administration has approved three R.S.V. vaccines. Two of them, GSK’s Arexvy and Pfizer’s Abrysvo, were approved in May last year and were administered during the fall and...
FDA approves RSV vaccine for adults ages 60 and up - NBC News
WEBMay 3, 2023 · The Food and Drug Administration on Wednesday approved the world's first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making....
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
FDA approves Moderna’s mRNA RSV vaccine for older adults
WEBMay 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the...
FDA advisers recommend world's first RSV vaccines, from ... - NBC News
WEBMar 1, 2023 · An FDA advisory committee has recommended that the agency approve two RSV vaccines for older people, one from Pfizer and another from GSK.
The race to an RSV vaccine is nearly over as shots await FDA ... - NBC News
WEBFeb 16, 2023 · RSV cases spiked dramatically in the U.S. earlier this winter, which overwhelmed children's hospitals — a reminder of the virus's threat. Since then, the pharmaceutical race to get vaccines to...
CDC study shows effectiveness of RSV immunization for infants
WEBMar 7, 2024 · New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
CDC and FDA Expedite the Availability of Additional Doses of New RSV …
WEBNov 16, 2023 · Today, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.